About this episode

Dr. Judith Finegold discusses how her clinical experience informs her approach to biotech investing.

Biotech investing often hinges on understanding science, trials and patient outcomes. Dr. Judith Finegold is a physician turned equity analyst, and she explains how her clinical experience helps assess drug pipelines, clinical trials and long term risk in biotech investing — well beyond the headlines. #CapGroupGlobal This content is intended to highlight issues and be of a general nature. It should not be considered advice, an endorsement or a recommendation. Products mentioned are not an offer of the product and may not be available for sale or purchase in all countries. All investments have risk, and you may lose money. Past results are not a guarantee of future results. Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This content is published by Capital Client Group, Inc., and copyrighted to Capital Group and affiliates, 2026, all rights reserved. For more information, including our detailed disclosures, visit www.capitalgroup.com/global-disclosures For our latest insights, practice management ideas and more, subscribe to Capital Ideas at…

More episodes of Capital Ideas Podcast

• 2026 Midyear Outlook · July 16, 2026 · 38 min
• How Chef Daniel Boulud scaled a restaurant empire with intention · July 9, 2026 · 24 min
• Balancing act: Investing amid the AI boom and the Iran war · July 2, 2026 · 25 min
• A hunting dog mindset to investing · June 25, 2026 · 26 min
• When will homes be affordable again? · June 18, 2026 · 23 min
• How relentless focus sets Broadcom's CEO apart · June 11, 2026 · 21 min

Explore listener stats, chart rankings, contacts and more on the Capital Ideas Podcast podcast page.